SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $4,974,000 | -2.4% | 115,000 | 0.0% | 0.33% | -7.5% |
Q3 2021 | $5,096,000 | +19.6% | 115,000 | +53.3% | 0.36% | +23.9% |
Q2 2021 | $4,261,000 | +196.7% | 75,000 | +50.0% | 0.29% | +43.8% |
Q1 2020 | $1,436,000 | -60.2% | 50,000 | 0.0% | 0.20% | -49.2% |
Q4 2019 | $3,610,000 | +28.7% | 50,000 | +150.0% | 0.40% | +12.5% |
Q3 2019 | $2,806,000 | -29.2% | 20,000 | -7.6% | 0.35% | -19.3% |
Q2 2019 | $3,962,000 | -51.8% | 21,639 | -58.1% | 0.44% | -54.6% |
Q1 2019 | $8,213,000 | -37.6% | 51,639 | -62.4% | 0.96% | -36.1% |
Q4 2018 | $13,156,000 | -25.3% | 137,339 | +10.1% | 1.50% | -14.8% |
Q3 2018 | $17,619,000 | -13.2% | 124,739 | -3.8% | 1.76% | -15.0% |
Q2 2018 | $20,299,000 | +32.7% | 129,679 | +36.5% | 2.08% | +10.1% |
Q1 2018 | $15,302,000 | -11.5% | 95,000 | -9.5% | 1.89% | -19.2% |
Q4 2017 | $17,283,000 | +454.8% | 104,930 | +109.9% | 2.34% | +486.7% |
Q3 2017 | $3,115,000 | -21.8% | 50,000 | 0.0% | 0.40% | -30.4% |
Q2 2017 | $3,982,000 | -22.9% | 50,000 | -31.2% | 0.57% | -30.1% |
Q1 2017 | $5,164,000 | – | 72,659 | – | 0.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Integral Health Asset Management, LLC | 311,000 | $10,294,000 | 2.68% |
Palo Alto Investors LP | 851,719 | $28,192,000 | 2.18% |
Boxer Capital, LLC | 1,094,000 | $36,211,000 | 1.86% |
DAFNA Capital Management LLC | 180,306 | $5,968,000 | 1.56% |
Deep Track Capital, LP | 675,000 | $22,343,000 | 1.43% |
Bellevue Group AG | 3,052,404 | $101,034,000 | 1.17% |
Ikarian Capital, LLC | 249,907 | $8,272,000 | 1.09% |
Ikarian Capital, LLC | 250,000 | $8,275,000 | 1.09% |
Artal Group S.A. | 750,000 | $24,825,000 | 1.04% |
SECTOR GAMMA AS | 118,476 | $3,922,000 | 0.85% |